TECX

Tectonic Therapeutic, Inc. (TECX) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company developing therapeutic proteins and antibodies targeting G-protein coupled receptors (GPCRs) using its proprietary GEODe platform. The company has no approved products and has not generated any revenue since inception. As of May 1, 2026, there were 18,869,186 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses rose 49% to $27.3 million from $18.3 million year-over-year.
  • R&D Expenses: Increased 60% to $20.9 million, driven primarily by $6.4 million in CRO/CDMO costs for the ongoing Phase 2 clinical trials of lead candidate TX45 and a $1.4 million increase in employee-related expenses (including stock-based compensation).
  • G&A Expenses: Increased 22% to $6.4 million, primarily due to higher employee-related costs and stock-based compensation.
• Capital Raise: The company utilized its At-The-Market (ATM) offering program for the first time, selling approximately 43,000 shares for net proceeds of $1.3 million. This contrasts with Q1 2025, which included $177.3 million in net proceeds from a private placement.
• Lease Obligations: Total liabilities increased significantly due to the commencement of a new operating lease for office and laboratory space in January 2026, recognizing a right-of-use asset of $3.7 million and a corresponding lease liability of $3.6 million.
• Interest Income: Decreased 11% to $2.2 million due to lower average cash balances compared to the prior year.

Guidance, Outlook, and Risks

• Clinical Progress:
  • TX45 (Pulmonary Hypertension): The APEX Phase 2 trial in HFpEF patients is ongoing. An Independent Data Monitoring Committee (IDMC) review in January 2026 concluded the trial could continue without modification. Topline results are expected late Q4 2026 or early Q1 2027. A new Phase 2 trial for PH-ILD (Group 3 PH) began screening in March 2026.
  • TX2100 (HHT): The Phase 1a healthy volunteer trial began in February 2026. As of April 2026, four cohorts have been dosed. Topline results are expected by the end of Q3 2026.
• Liquidity Outlook: Management believes existing cash and cash equivalents ($236.9 million) are sufficient to fund operations for at least the next 12 months. The company expects to continue incurring significant losses as it advances clinical programs.
• Key Risks:
  • Supply Chain & Geopolitics: The company relies on WuXi Biologics in China as the sole source manufacturer for TX45. Risks include potential supply disruptions due to U.S.-China trade tensions, tariffs, and the BIOSECURE Act (signed Dec 2025), which restricts U.S. government procurement from certain Chinese biotechnology entities.
  • Regulatory & Clinical Uncertainty: Clinical trials are inherently uncertain; failure to demonstrate safety or efficacy could halt development. The company faces competition and potential regulatory changes in the EU and U.S.
  • Capital Needs: Substantial additional funding will be required to complete development and commercialization. Future financing may be dilutive or unavailable on acceptable terms.

Investor Verification Checklist

• Verify the status and enrollment rates of the TX45 APEX Phase 2 trial and the new PH-ILD Phase 2 trial.
• Confirm the timeline for topline data release for TX45 (late 2026/early 2027) and TX2100 (Q3 2026).
• Assess the impact of the BIOSECURE Act and U.S.-China trade relations on the sole-source manufacturing relationship with WuXi Biologics.
• Monitor cash burn rate relative to the $236.9 million cash balance to validate the 12-month liquidity runway.
• Review future capital raising plans, specifically the remaining capacity under the $100 million ATM program and potential need for additional equity or debt financing.